Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile X mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 3, 2014, Pages 393-401

  Sun, Miao Kun ^a   Hongpaisan, Jarin ^a   Lim, Chol Seung ^a   Alkon, Daniel L ^a  

^a Blanchette Rockefeller Neurosciences Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRYOSTATIN 1; GLYCOGEN SYNTHASE KINASE 3BETA; METABOTROPIC RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MATURATION; CELL TRANSFORMATION; CONTROLLED STUDY; DENDRITIC SPINE; DRUG MECHANISM; EXECUTIVE FUNCTION; FRAGILE X SYNDROME; HIPPOCAMPUS; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PHENOTYPE; POSTSYNAPTIC DENSITY; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; SENSORIMOTOR FUNCTION; SPATIAL LEARNING; SPATIAL MEMORY; SYNAPSE VESICLE; SYNAPTIC MEMBRANE; SYNAPTOGENESIS;

ANIMALS; BRYOSTATINS; DENDRITIC SPINES; DISEASE MODELS, ANIMAL; FRAGILE X SYNDROME; HIPPOCAMPUS; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED STRAINS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; PROTEIN KINASE C-EPSILON; SPATIAL BEHAVIOR; SYNAPSES;

EID: 84901191804     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214098     Document Type: Article

References (60)

1. Alkon DL, Epstein H, Kuzirian A, Bennett MC, and Nelson TJ (2005) Protein synthesis required for long-term memory is induced by PKC activation on days before associative learning. Proc Natl Acad Sci USA 102:16432-16437.
2. Alkon DL, Sun M-K, and Nelson TJ (2007) PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol Sci 28:51-60.
3. Ashley CT, Jr, Wilkinson KD, Reines D, and Warren ST (1993) FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262:563-566.
4. Bhattacharya A and Klann E (2012) Fragile X syndrome therapeutics S(C)TEP through the developmental window. Neuron 74:1-3.
5. Bhogal B and Jongens TA (2010) Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention. Dis Model Mech 3:693-700.
6. Connor SA, Hoeffer CA, Klann E, and Nguyen PV (2011) Fragile X mental retardation protein regulates heterosynaptic plasticity in the hippocampus. Learn Mem 18:207-220.
7. Cruz-Martín A, Crespo M, and Portera-Cailliau C (2010) Delayed stabilization of dendritic spines in fragile X mice. J Neurosci 30:7793-7803.
8. Darnell JC and Klann E (2013) The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 16:1530-1536.
9. DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, and Wender PA (2012) Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 4:705-710.
10. A receptor: a novel target for treatment of fragile X? Trends Neurosci 30:425-431.
11. A receptor in fragile X syndrome. Brain Res 1121:238-245.
12. Garber KB, Visootsak J, and Warren ST (2008) Fragile X syndrome. Eur J Hum Genet 16:666-672.
13. Gereau RW 4th and Heinemann SF (1998) Role of protein kinase C phosphorylation in rapid desensitization of metabotropic glutamate receptor 5. Neuron 20:143-151.
14. Gonçalves JT, Anstey JE, Golshani P, and Portera-Cailliau C (2013) Circuit level defects in the developing neocortex of fragile X mice. Nat Neurosci 16:903-909.
15. Graham B and Redman S (1994) A simulation of action potentials in synaptic boutons during presynaptic inhibition. J Neurophysiol 71:538-549.
16. Grossman AW, Aldridge GM, Weiler IJ, and Greenough WT (2006) Local protein synthesis and spine morphogenesis: fragile X syndrome and beyond. J Neurosci 26: 7151-7155.
17. Guo W, Murthy AC, Zhang L, Johnson EB, Schaller EG, Allan AM, and Zhao X (2012) Inhibition of GSK3b improves hippocampus-dependent learning and rescues neu-rogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 21:681-691.
18. Hajós M (2014) Portraying inhibition of metabotropic glutamate receptor 5 in fragile X mice. Biol Psychiatry 75:177-178.
19. Harlow EG, Till SM, Russell TA, Wijetunge LS, Kind P, and Contractor A (2010) Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice. Neuron 65:385-398.
20. He Q, Nomura T, Xu J, and Contractor A (2014) The developmental switch in GABA polarity is delayed in Fragile X mice. J Neurosci 34:446-450.
21. Heulens I, D'Hulst C, Van Dam D, De Deyn PP, and Kooy RF (2012) Pharmacological treatment of Fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res 229:244-249.
22. Hongpaisan J and Alkon DL (2007) A structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC. Proc Natl Acad Sci USA 104:19571-19576.
23. Hongpaisan J, Sun M-K, and Alkon DL (2011) PKC " activation prevents synaptic loss, Ab elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J Neurosci 31:630-643.
24. Kaufmann WE, Abrams MT, Chen W, and Reiss AL (1999) Genotype, molecular phenotype, and cognitive phenotype: correlations in Fragile X syndrome. Am J Med Genet 83:286-295.
25. Kirov SA, Petrak LJ, Fiala JC, and Harris KM (2004) Dendritic spines disappear with chilling but proliferate excessively upon rewarming of mature hippocampus. Neuroscience 127:69-80.
26. Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, Maex R, De Graaf W, Smit AE, VanderWerf F, and Bakker CE, et al. (2005) Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron 47: 339-352.
27. Lauterborn JC, Rex CS, Kramár E, Chen LY, Pandyarajan V, Lynch G, and Gall CM (2007) Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of Fragile X syndrome. J Neurosci 27:10685-10694.
28. Ludwig AL, Espinal GM, Pretto DI, Jamal AL, Arque G, Tassone F, Berman RF, and Hagerman PJ (2014) CNS expression of murine Fragile X protein (FMRP) as a function of CGG-repeat size. Hum Mol Genet [published ahead of print].
29. Lüscher C and Huber KM (2010) Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65: 445-459.
30. McLennan Y, Polussa J, Tassone F, and Hagerman R (2011) Fragile X syndrome. Curr Genomics 12:216-224.
31. Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, and Bauchwitz RP (2009) Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 56: 463-472.
32. Nelson TJ, Sun M-K, Hongpaisan J, and Alkon DL (2008) Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. Eur J Pharmacol 585:76-87.
33. Nelson TJ, Cui C, Luo Y, and Alkon DL (2009) Reduction of beta-Amyloid levels by novel protein kinase C (epsilon) activators. J Biol Chem 284:34514-34521.
34. Niere F, Wilkerson JR, and Huber KM (2012) Evidence for a Fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. J Neurosci 32: 5924-5936.
35. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, and Huntsman MM (2010) Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of Fragile X syndrome. J Neurosci 30:9929-9938.
36. Padmashri R, Reiner BC, Suresh A, Spartz E, and Dunaevsky A (2013) Altered structural and functional synaptic plasticity with motor skill learning in a mouse model of Fragile X syndrome. J Neurosci 33:19715-19723.
37. Paluszkiewicz SM, Martin BS, and Huntsman MM (2011) Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci 33:349-364.
38. Pfeiffer BE, Zang T, Wilkerson JR, Taniguchi M, Maksimova MA, Smith LN, Cowan CW, and Huber KM (2010) Fragile X mental retardation protein is required for synapse elimination by the activity-dependent transcription factor MEF2. Neuron 66:191-197.
39. Ronesi JA, Collins KA, Hays SA, Tsai NP, Guo W, Birnbaum SG, Hu JH, Worley PF, Gibson JR, and Huber KM (2012) Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of Fragile X syndrome. Nat Neurosci 15: 431-440, S1.
40. Routh BN, Johnston D, and Brager DH (2013) Loss of functional A-type potassium channels in the dendrites of CA1 pyramidal neurons from a mouse model of Fragile X syndrome. J Neurosci 33:19442-19450.
41. Sabaratnam M, Murthy NV, Wijeratne A, Buckingham A, and Payne S (2003) Autistic-like behaviour profile and psychiatric morbidity in fragile X syndrome: a prospective ten-year follow-up study. Eur Child Adolesc Psychiatry 12:172-177.
42. Santoro MR, Bray SM, and Warren ST (2012) Molecular mechanisms of Fragile X syndrome: a twenty-year perspective. Annu Rev Pathol 7:219-245.
43. Schaeffer C, Beaulande M, Ehresmann C, Ehresmann B, and Moine H (2003) The RNA binding protein FMRP: new connections and missing links. Biol Cell 95: 221-228.
44. Scotto-Lomassese S, Nissant A, Mota T, Néant-Féry M, Oostra BA, Greer CA, Lledo PM, Trembleau A, and Caillé I (2011) Fragile X mental retardation protein regulates new neuron differentiation in the adult olfactory bulb. J Neurosci 31: 2205-2215.
45. Sorra KE and Harris KM (2000) Overview on the structure, composition, function, development, and plasticity of hippocampal dendritic spines. Hippocampus 10: 501-511.
46. Sun M-K and Alkon DL (2005) Dual effects of bryostatin-1 on spatial memory and depression. Eur J Pharmacol 512:43-51.
47. Sun M-K, Hongpaisan J, Nelson TJ, and Alkon DL (2008) Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains. Proc Natl Acad Sci USA 105:13620-13625.
48. Szallasi Z, Smith CB, Pettit GR, and Blumberg PM (1994) Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-Acetate in NIH 3T3 fibroblasts. J Biol Chem 269:2118-2124.
49. Van der Molen MJ, Huizinga M, Huizenga HM, Ridderinkhof KR, Van der Molen MW, Hamel BJ, Curfs LM, and RamakersGJ (2010) Profiling fragile X syndrome in males: strengths and weaknesses in cognitive abilities. Res Dev Disabil 31:426-439.
50. Vinueza Veloz MF, Buijsen RA, Willemsen R, Cupido A, Bosman LW, Koekkoek SK, Potters JW, Oostra BA, and De Zeeuw CI (2012) The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav 11:325-331.
51. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, and Zhang FP, et al. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in Fragile X syndrome. Cell 65:905-914.
52. Vislay RL, Martin BS, Olmos-Serrano JL, Kratovac S, Nelson DL, Corbin JG, and Huntsman MM (2013) Homeostatic responses fail to correct defective amygdala inhibitory circuit maturation in Fragile X syndrome. J Neurosci 33: 7548-7558.
53. Wang X, Snape M, Klann E, Stone JG, Singh A, Petersen RB, Castellani RJ, Casa-desus G, Smith MA, and Zhu X (2012) Activation of the extracellular signalregulated kinase pathway contributes to the behavioral deficit of fragile X-syn-drome. J Neurochem 121:672-679.
54. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, Comery TA, Patel B, Eberwine J, and Greenough WT (1997) Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci USA 94:5395-5400.
55. Wender PA, Cribbs CM, Koehler KF, Sharkey NA, Herald CL, Kamano Y, Pettit GR, and Blumberg PM (1988) Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc Natl Acad Sci USA 85:7197-7201.
56. Wender PA, Baryza JL, Brenner SE, DeChristopher BA, Loy BA, Schrier AJ, and Verma VA (2011) Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc Natl Acad Sci USA 108: 6721-6726.
57. Westmark CJ, Westmark PR, O'Riordan KJ, Ray BC, Hervey CM, Salamat MS, Abozeid SH, Stein KM, Stodola LA, and Tranfaglia M, et al. (2011) Reversal of Fragile X phenotypes by manipulation of AbPP/Ab levels in Fmr1KO mice. PLoS ONE 6:e26549.
58. Yang JC, Simon C, Niu YQ, Bogost M, Schneider A, Tassone F, Seritan A, Grigsby J, Hagerman PJ, and Hagerman RJ, et al. (2013) Phenotypes of hypofrontality in older female Fragile X premutation carriers. Ann Neurol 74:275-283.
59. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, and Jope RS (2010) Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 79:632-646.
60. Zalfa F, Eleuteri B, Dickson KS, Mercaldo V, De Rubeis S, di Penta A, Tabolacci E, Chiurazzi P, Neri G, and Grant SG, et al. (2007) A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci 10:578-587.